2024-10-19209 Pages3880 USD
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disease characterized by muscle weakness and fatigue. It occurs when communication between nerves and muscles is impaired, leading to muscle weakness, drooping eyelids, double vision, and difficulties with speech, chewing, swallowing, and breathing. The primary treatment goal for MG is to manage symptoms, improve neuromuscular transmission, and suppress the autoimmune response. Common treatment options include acetylcholinesterase inhibitors, immunosuppressants, corticosteroids, plasma exchange, and intravenous immunoglobulin therapy. In severe cases, thymectomy may be recommended to remove the thymus gland, which is often associated with MG.
The market for Myasthenia Gravis (MG) treatment is witnessing significant growth driven